The global market for RNA-Based Therapeutics and Vaccines was valued at US$ 63.5 million in the year 2024 and is projected to reach a revised size of US$ 1459 million by 2031, growing at a CAGR of 57.3% during the forecast period.

RNA-Based Therapeutics and Vaccines Market

RNA-based biopharmaceuticals, which includes therapeutics and vaccines, is a relatively new class of treatment and prophylactic for a number of chronic and rare diseases, including cancer, diabetes, tuberculosis and certaincardiovascular conditions.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for RNA-Based Therapeutics and Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNA-Based Therapeutics and Vaccines.

The RNA-Based Therapeutics and Vaccines market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global RNA-Based Therapeutics and Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the RNA-Based Therapeutics and Vaccines companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of RNA-Based Therapeutics and Vaccines Market Report

Report Metric	Details
Report Name	RNA-Based Therapeutics and Vaccines Market
Accounted market size in year	US$ 63.5 million
Forecasted market size in 2031	US$ 1459 million
CAGR	57.3%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	RNA-Based Therapeutics RNA-Based Vaccines
Segment by Application	Oncology Immunology Ophthalmology Cardiovascular Diseases Infectious Diseases Genetic Diseases Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Alnylam Pharmaceuticals, Arbutus Biopharma, Arrowhead Pharmaceuticals, BioNTech, CureVac, Dicerna Pharmaceuticals, Regulus Therapeutics, Marina Biotech, MiRagen Therapeutics, Moderna Therapeutics, Quark Pharmaceuticals, Roche, Sylentis
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNA-Based Therapeutics and Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is RNA-Based Therapeutics and Vaccines Market growing?

Ans: The RNA-Based Therapeutics and Vaccines Market witnessing a CAGR of 57.3% during the forecast period 2025-2031.

What is the RNA-Based Therapeutics and Vaccines Market size in 2031?

Ans: The RNA-Based Therapeutics and Vaccines Market size in 2031 will be US$ 1459 million.

Who are the main players in the RNA-Based Therapeutics and Vaccines Market report?

Ans: The main players in the RNA-Based Therapeutics and Vaccines Market are Alnylam Pharmaceuticals, Arbutus Biopharma, Arrowhead Pharmaceuticals, BioNTech, CureVac, Dicerna Pharmaceuticals, Regulus Therapeutics, Marina Biotech, MiRagen Therapeutics, Moderna Therapeutics, Quark Pharmaceuticals, Roche, Sylentis

What are the Application segmentation covered in the RNA-Based Therapeutics and Vaccines Market report?

Ans: The Applications covered in the RNA-Based Therapeutics and Vaccines Market report are Oncology, Immunology, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Genetic Diseases, Others

What are the Type segmentation covered in the RNA-Based Therapeutics and Vaccines Market report?

Ans: The Types covered in the RNA-Based Therapeutics and Vaccines Market report are RNA-Based Therapeutics, RNA-Based Vaccines

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global RNA-Based Therapeutics and Vaccines Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 RNA-Based Therapeutics

1.2.3 RNA-Based Vaccines

1.3 Market by Application

1.3.1 Global RNA-Based Therapeutics and Vaccines Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Oncology

1.3.3 Immunology

1.3.4 Ophthalmology

1.3.5 Cardiovascular Diseases

1.3.6 Infectious Diseases

1.3.7 Genetic Diseases

1.3.8 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global RNA-Based Therapeutics and Vaccines Market Perspective (2020-2031)

2.2 Global RNA-Based Therapeutics and Vaccines Growth Trends by Region

2.2.1 Global RNA-Based Therapeutics and Vaccines Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 RNA-Based Therapeutics and Vaccines Historic Market Size by Region (2020-2025)

2.2.3 RNA-Based Therapeutics and Vaccines Forecasted Market Size by Region (2026-2031)

2.3 RNA-Based Therapeutics and Vaccines Market Dynamics

2.3.1 RNA-Based Therapeutics and Vaccines Industry Trends

2.3.2 RNA-Based Therapeutics and Vaccines Market Drivers

2.3.3 RNA-Based Therapeutics and Vaccines Market Challenges

2.3.4 RNA-Based Therapeutics and Vaccines Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top RNA-Based Therapeutics and Vaccines Players by Revenue

3.1.1 Global Top RNA-Based Therapeutics and Vaccines Players by Revenue (2020-2025)

3.1.2 Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Players (2020-2025)

3.2 Global RNA-Based Therapeutics and Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by RNA-Based Therapeutics and Vaccines Revenue

3.4 Global RNA-Based Therapeutics and Vaccines Market Concentration Ratio

3.4.1 Global RNA-Based Therapeutics and Vaccines Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by RNA-Based Therapeutics and Vaccines Revenue in 2024

3.5 Global Key Players of RNA-Based Therapeutics and Vaccines Head office and Area Served

3.6 Global Key Players of RNA-Based Therapeutics and Vaccines, Product and Application

3.7 Global Key Players of RNA-Based Therapeutics and Vaccines, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 RNA-Based Therapeutics and Vaccines Breakdown Data by Type

4.1 Global RNA-Based Therapeutics and Vaccines Historic Market Size by Type (2020-2025)

4.2 Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Type (2026-2031)

5 RNA-Based Therapeutics and Vaccines Breakdown Data by Application

5.1 Global RNA-Based Therapeutics and Vaccines Historic Market Size by Application (2020-2025)

5.2 Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America RNA-Based Therapeutics and Vaccines Market Size (2020-2031)

6.2 North America RNA-Based Therapeutics and Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America RNA-Based Therapeutics and Vaccines Market Size by Country (2020-2025)

6.4 North America RNA-Based Therapeutics and Vaccines Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe RNA-Based Therapeutics and Vaccines Market Size (2020-2031)

7.2 Europe RNA-Based Therapeutics and Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe RNA-Based Therapeutics and Vaccines Market Size by Country (2020-2025)

7.4 Europe RNA-Based Therapeutics and Vaccines Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size (2020-2031)

8.2 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size by Region (2020-2025)

8.4 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America RNA-Based Therapeutics and Vaccines Market Size (2020-2031)

9.2 Latin America RNA-Based Therapeutics and Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America RNA-Based Therapeutics and Vaccines Market Size by Country (2020-2025)

9.4 Latin America RNA-Based Therapeutics and Vaccines Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size (2020-2031)

10.2 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size by Country (2020-2025)

10.4 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Alnylam Pharmaceuticals

11.1.1 Alnylam Pharmaceuticals Company Details

11.1.2 Alnylam Pharmaceuticals Business Overview

11.1.3 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction

11.1.4 Alnylam Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025)

11.1.5 Alnylam Pharmaceuticals Recent Development

11.2 Arbutus Biopharma

11.2.1 Arbutus Biopharma Company Details

11.2.2 Arbutus Biopharma Business Overview

11.2.3 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Introduction

11.2.4 Arbutus Biopharma Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025)

11.2.5 Arbutus Biopharma Recent Development

11.3 Arrowhead Pharmaceuticals

11.3.1 Arrowhead Pharmaceuticals Company Details

11.3.2 Arrowhead Pharmaceuticals Business Overview

11.3.3 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction

11.3.4 Arrowhead Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025)

11.3.5 Arrowhead Pharmaceuticals Recent Development

11.4 BioNTech

11.4.1 BioNTech Company Details

11.4.2 BioNTech Business Overview

11.4.3 BioNTech RNA-Based Therapeutics and Vaccines Introduction

11.4.4 BioNTech Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025)

11.4.5 BioNTech Recent Development

11.5 CureVac

11.5.1 CureVac Company Details

11.5.2 CureVac Business Overview

11.5.3 CureVac RNA-Based Therapeutics and Vaccines Introduction

11.5.4 CureVac Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025)

11.5.5 CureVac Recent Development

11.6 Dicerna Pharmaceuticals

11.6.1 Dicerna Pharmaceuticals Company Details

11.6.2 Dicerna Pharmaceuticals Business Overview

11.6.3 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction

11.6.4 Dicerna Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025)

11.6.5 Dicerna Pharmaceuticals Recent Development

11.7 Regulus Therapeutics

11.7.1 Regulus Therapeutics Company Details

11.7.2 Regulus Therapeutics Business Overview

11.7.3 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Introduction

11.7.4 Regulus Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025)

11.7.5 Regulus Therapeutics Recent Development

11.8 Marina Biotech

11.8.1 Marina Biotech Company Details

11.8.2 Marina Biotech Business Overview

11.8.3 Marina Biotech RNA-Based Therapeutics and Vaccines Introduction

11.8.4 Marina Biotech Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025)

11.8.5 Marina Biotech Recent Development

11.9 MiRagen Therapeutics

11.9.1 MiRagen Therapeutics Company Details

11.9.2 MiRagen Therapeutics Business Overview

11.9.3 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Introduction

11.9.4 MiRagen Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025)

11.9.5 MiRagen Therapeutics Recent Development

11.10 Moderna Therapeutics

11.10.1 Moderna Therapeutics Company Details

11.10.2 Moderna Therapeutics Business Overview

11.10.3 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Introduction

11.10.4 Moderna Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025)

11.10.5 Moderna Therapeutics Recent Development

11.11 Quark Pharmaceuticals

11.11.1 Quark Pharmaceuticals Company Details

11.11.2 Quark Pharmaceuticals Business Overview

11.11.3 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction

11.11.4 Quark Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025)

11.11.5 Quark Pharmaceuticals Recent Development

11.12 Roche

11.12.1 Roche Company Details

11.12.2 Roche Business Overview

11.12.3 Roche RNA-Based Therapeutics and Vaccines Introduction

11.12.4 Roche Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025)

11.12.5 Roche Recent Development

11.13 Sylentis

11.13.1 Sylentis Company Details

11.13.2 Sylentis Business Overview

11.13.3 Sylentis RNA-Based Therapeutics and Vaccines Introduction

11.13.4 Sylentis Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025)

11.13.5 Sylentis Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Alnylam Pharmaceuticals

Arbutus Biopharma

Arrowhead Pharmaceuticals

BioNTech

CureVac

Dicerna Pharmaceuticals

Quark Pharmaceuticals

Roche

Sylentis

List of Tables

Table 1. Global RNA-Based Therapeutics and Vaccines Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of RNA-Based Therapeutics

Table 3. Key Players of RNA-Based Vaccines

Table 4. Global RNA-Based Therapeutics and Vaccines Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global RNA-Based Therapeutics and Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global RNA-Based Therapeutics and Vaccines Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global RNA-Based Therapeutics and Vaccines Market Share by Region (2020-2025)

Table 8. Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global RNA-Based Therapeutics and Vaccines Market Share by Region (2026-2031)

Table 10. RNA-Based Therapeutics and Vaccines Market Trends

Table 11. RNA-Based Therapeutics and Vaccines Market Drivers

Table 12. RNA-Based Therapeutics and Vaccines Market Challenges

Table 13. RNA-Based Therapeutics and Vaccines Market Restraints

Table 14. Global RNA-Based Therapeutics and Vaccines Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global RNA-Based Therapeutics and Vaccines Market Share by Players (2020-2025)

Table 16. Global Top RNA-Based Therapeutics and Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA-Based Therapeutics and Vaccines as of 2024)

Table 17. Ranking of Global Top RNA-Based Therapeutics and Vaccines Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by RNA-Based Therapeutics and Vaccines Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of RNA-Based Therapeutics and Vaccines, Headquarters and Area Served

Table 20. Global Key Players of RNA-Based Therapeutics and Vaccines, Product and Application

Table 21. Global Key Players of RNA-Based Therapeutics and Vaccines, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global RNA-Based Therapeutics and Vaccines Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Type (2020-2025)

Table 25. Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Type (2026-2031)

Table 27. Global RNA-Based Therapeutics and Vaccines Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Application (2020-2025)

Table 29. Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Application (2026-2031)

Table 31. North America RNA-Based Therapeutics and Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America RNA-Based Therapeutics and Vaccines Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America RNA-Based Therapeutics and Vaccines Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe RNA-Based Therapeutics and Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe RNA-Based Therapeutics and Vaccines Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe RNA-Based Therapeutics and Vaccines Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America RNA-Based Therapeutics and Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America RNA-Based Therapeutics and Vaccines Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America RNA-Based Therapeutics and Vaccines Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size by Country (2026-2031) & (US$ Million)

Table 46. Alnylam Pharmaceuticals Company Details

Table 47. Alnylam Pharmaceuticals Business Overview

Table 48. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Product

Table 49. Alnylam Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025) & (US$ Million)

Table 50. Alnylam Pharmaceuticals Recent Development

Table 51. Arbutus Biopharma Company Details

Table 52. Arbutus Biopharma Business Overview

Table 53. Arbutus Biopharma RNA-Based Therapeutics and Vaccines Product

Table 54. Arbutus Biopharma Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025) & (US$ Million)

Table 55. Arbutus Biopharma Recent Development

Table 56. Arrowhead Pharmaceuticals Company Details

Table 57. Arrowhead Pharmaceuticals Business Overview

Table 58. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Product

Table 59. Arrowhead Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025) & (US$ Million)

Table 60. Arrowhead Pharmaceuticals Recent Development

Table 61. BioNTech Company Details

Table 62. BioNTech Business Overview

Table 63. BioNTech RNA-Based Therapeutics and Vaccines Product

Table 64. BioNTech Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025) & (US$ Million)

Table 65. BioNTech Recent Development

Table 66. CureVac Company Details

Table 67. CureVac Business Overview

Table 68. CureVac RNA-Based Therapeutics and Vaccines Product

Table 69. CureVac Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025) & (US$ Million)

Table 70. CureVac Recent Development

Table 71. Dicerna Pharmaceuticals Company Details

Table 72. Dicerna Pharmaceuticals Business Overview

Table 73. Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Product

Table 74. Dicerna Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025) & (US$ Million)

Table 75. Dicerna Pharmaceuticals Recent Development

Table 76. Regulus Therapeutics Company Details

Table 77. Regulus Therapeutics Business Overview

Table 78. Regulus Therapeutics RNA-Based Therapeutics and Vaccines Product

Table 79. Regulus Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025) & (US$ Million)

Table 80. Regulus Therapeutics Recent Development

Table 81. Marina Biotech Company Details

Table 82. Marina Biotech Business Overview

Table 83. Marina Biotech RNA-Based Therapeutics and Vaccines Product

Table 84. Marina Biotech Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025) & (US$ Million)

Table 85. Marina Biotech Recent Development

Table 86. MiRagen Therapeutics Company Details

Table 87. MiRagen Therapeutics Business Overview

Table 88. MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Product

Table 89. MiRagen Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025) & (US$ Million)

Table 90. MiRagen Therapeutics Recent Development

Table 91. Moderna Therapeutics Company Details

Table 92. Moderna Therapeutics Business Overview

Table 93. Moderna Therapeutics RNA-Based Therapeutics and Vaccines Product

Table 94. Moderna Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025) & (US$ Million)

Table 95. Moderna Therapeutics Recent Development

Table 96. Quark Pharmaceuticals Company Details

Table 97. Quark Pharmaceuticals Business Overview

Table 98. Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Product

Table 99. Quark Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025) & (US$ Million)

Table 100. Quark Pharmaceuticals Recent Development

Table 101. Roche Company Details

Table 102. Roche Business Overview

Table 103. Roche RNA-Based Therapeutics and Vaccines Product

Table 104. Roche Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025) & (US$ Million)

Table 105. Roche Recent Development

Table 106. Sylentis Company Details

Table 107. Sylentis Business Overview

Table 108. Sylentis RNA-Based Therapeutics and Vaccines Product

Table 109. Sylentis Revenue in RNA-Based Therapeutics and Vaccines Business (2020-2025) & (US$ Million)

Table 110. Sylentis Recent Development

Table 111. Research Programs/Design for This Report

Table 112. Key Data Information from Secondary Sources

Table 113. Key Data Information from Primary Sources

Table 114. Authors List of This Report

List of Figures

Figure 1. RNA-Based Therapeutics and Vaccines Picture

Figure 2. Global RNA-Based Therapeutics and Vaccines Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global RNA-Based Therapeutics and Vaccines Market Share by Type: 2024 VS 2031

Figure 4. RNA-Based Therapeutics Features

Figure 5. RNA-Based Vaccines Features

Figure 6. Global RNA-Based Therapeutics and Vaccines Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global RNA-Based Therapeutics and Vaccines Market Share by Application: 2024 VS 2031

Figure 8. Oncology Case Studies

Figure 9. Immunology Case Studies

Figure 10. Ophthalmology Case Studies

Figure 11. Cardiovascular Diseases Case Studies

Figure 12. Infectious Diseases Case Studies

Figure 13. Genetic Diseases Case Studies

Figure 14. Others Case Studies

Figure 15. RNA-Based Therapeutics and Vaccines Report Years Considered

Figure 16. Global RNA-Based Therapeutics and Vaccines Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 17. Global RNA-Based Therapeutics and Vaccines Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 18. Global RNA-Based Therapeutics and Vaccines Market Share by Region: 2024 VS 2031

Figure 19. Global RNA-Based Therapeutics and Vaccines Market Share by Players in 2024

Figure 20. Global Top RNA-Based Therapeutics and Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA-Based Therapeutics and Vaccines as of 2024)

Figure 21. The Top 10 and 5 Players Market Share by RNA-Based Therapeutics and Vaccines Revenue in 2024

Figure 22. North America RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. North America RNA-Based Therapeutics and Vaccines Market Share by Country (2020-2031)

Figure 24. United States RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Canada RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe RNA-Based Therapeutics and Vaccines Market Share by Country (2020-2031)

Figure 28. Germany RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. France RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. U.K. RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Italy RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Russia RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Nordic Countries RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific RNA-Based Therapeutics and Vaccines Market Share by Region (2020-2031)

Figure 36. China RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Japan RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. South Korea RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Southeast Asia RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. India RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Australia RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America RNA-Based Therapeutics and Vaccines Market Share by Country (2020-2031)

Figure 44. Mexico RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Brazil RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa RNA-Based Therapeutics and Vaccines Market Share by Country (2020-2031)

Figure 48. Turkey RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Saudi Arabia RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. UAE RNA-Based Therapeutics and Vaccines Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Alnylam Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2020-2025)

Figure 52. Arbutus Biopharma Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2020-2025)

Figure 53. Arrowhead Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2020-2025)

Figure 54. BioNTech Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2020-2025)

Figure 55. CureVac Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2020-2025)

Figure 56. Dicerna Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2020-2025)

Figure 57. Regulus Therapeutics Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2020-2025)

Figure 58. Marina Biotech Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2020-2025)

Figure 59. MiRagen Therapeutics Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2020-2025)

Figure 60. Moderna Therapeutics Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2020-2025)

Figure 61. Quark Pharmaceuticals Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2020-2025)

Figure 62. Roche Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2020-2025)

Figure 63. Sylentis Revenue Growth Rate in RNA-Based Therapeutics and Vaccines Business (2020-2025)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Pharmacy Chatbot Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10T20319

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Inline Pharmaceutical Packaging Leak Detection System Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-6Q20319

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Radiological Marker Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-35Z19949

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Pharmaceutical Biomanufacturing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-26E19785

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions